NCT03594396进行中（未招募）1 期
Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) Before Standard Neoadjuvant Chemotherapy for Stage II/III Triple Negative or Low ER+ Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- The changes of tumor biology
研究概览
简要总结
Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) before Standard Neoadjuvant Chemotherapy for Stage II/III Triple Negative or Low ER+ Breast Cancer
详细描述
This is a non-randomized, prospective, open label, window pilot study to evaluate the change of tumor biology after olaparib and durvalumab treatment by serial biopsy of breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Nineteen years of age or older on the day of signing informed consent.
- •Willing and able to provide written informed consent for voluntary participation in the trial.
- •Has previously untreated, clinical stage II/III triple negative breast cancer (TNBC) or low estrogen receptor (ER) tumor where ER is expressed in ≤10% tumor cells) .
- •Willing to provide biopsies from the primary tumor or lymph nodes at screening to the central laboratory and agrees to have a core needle biopsy or incisional or excisional tumor biopsy after 14 days and 28 days of olaparib treatment (before and after durvalumab treatment) if tumor biopsy is feasible as judged by the investigator.
- •Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥60 years old and no menses for >1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry and agree to use contraception if they or their partner are of reproductive potential.
- •Has adequate organ function.
- •Hemoglobin ≥ 10.0 g/dL
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (> 1500 per mm3)
- •Platelet count ≥ 100 x 109/L (>100,000 per mm3)
- •Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
- •AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN unless due to Gilbert's syndrome
- •INR/PT/APTT each ≤ 1.5 x ULN
- •TSH within normal limits
- •Serum creatinine < 1.5 x ULN or serum creatinine CL > 51 mL/min by the Cockcroft-Gault formula (Cockroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance
- •Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
排除标准
- •Underweighted populations - ≤30kg
- •Has evidence of metastatic breast cancer, inflammatory breast cancer, or concurrent bilateral invasive breast cancer where ER is expressed in >10% tumor cells.
- •(Note) Patients with bilateral invasive breast cancers can be enrolled if both tumors are TNBCs, including low estrogen receptor (ER) tumor where ER is expressed in ≤10% tumor cells.
- •Has another malignancy within the last 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and thyroid cancer that has undergone potentially curative surgery, or in situ cervical cancer.
- •(Note) These patients should be consulted to the principal investigator for a case-by-case decision before enrollment.
- •Has received prior chemotherapy, targeted therapy, radiation therapy, immunotherapy that targets immune checkpoints, co-stimulatory or co-inhibitory pathways for T cell receptors within the past 12 months.
- •Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
- •Is currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
- •Has received a live vaccine within 30 days of the first dose of durvalumab. Note: Patients, if enrolled, should not receive live vaccine up to 30 days after the last dose of IP.
- •Has an active autoimmune disease or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]) that has required systemic treatment in past 2 years. The followings are exceptions to this criterion:
- •Patients with vitiligo or alopecia
- •Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment.
- •Any chronic skin condition that does not require systemic therapy
- •Patients without active disease in the last 3 years may be included but only after consultation with the principal investigator.
- •Patients with celiac disease controlled by diet alone may be included but only after consultation with the principal investigator.
- •Has a diagnosis of immunodeficiency
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
- •Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)
- •Systemic corticosteroid at physiologic dose not to exceed 10 mg/day of prednisone or its equivalent
- •Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
- •Has a known history of Human Immunodeficiency Virus (HIV).
- •Active infection, including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B, hepatitis C, or human immunodeficiency virus (HIV, positive HIV 1 or 2 antibodies). Active hepatitis B virus (HBV) infection is defined by a positive HBV surface antigen (HBsAg) and positive titer for HBV DNA.result. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core IgG antibody and the absence of HBsAg, deoxyribonucleic acid [DNA] negative) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)..
- •Has evidence of active, non-infectious pneumonitis.
- •Has history of pneumonitis requiring treatment with steroids or history of interstitial lung disease.
- •Has an active infection requiring systemic therapy.
- •Has significant cardiovascular disease, such as: History of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months; Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA class III or IV
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- •Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.
- •Has a known hypersensitivity to the components of the study drug or its analogs.
- •Concurrent use of any medications or substances that are strong inhibitors of cytochrome P450 (CYP) 3A (CYP3A), such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir, or strong inducers of CYP3A
- •Dihydropyridine calcium-channel blockers are permitted for management of hypertension.
- •Previous allogenic bone marrow transplant or (single) umbilical cord blood transplantation
- •Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable, as long as not received within 28 days of start of treatment.
- •Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction within 14 days of treatment
- •Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •Subjects with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
- •Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician
- •Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- •History of leptomeningeal carcinomatosis
研究组 & 干预措施
MEDIOLA
Experimental
Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.
Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.
On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT.
干预措施: Olaparib (Drug)
MEDIOLA
Experimental
Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.
Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.
On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT.
干预措施: Durvalumab (Drug)
结局指标
主要结局
The changes of tumor biology
时间窗: 28 days
The changes of tumor biology detected by serial biopsy of breast cancer before and after olaparib and durvalumab (exploratory serial biopsy study)
次要结局
- Treatment-related adverse events as assessed by CTCAE v4.0(7 months)
- Response rate(7 months)
- Adverse events of special interest and immune-mediated adverse events(7 months)
- pathological complete response(7 months)
研究者
Seock-Ah Im
Professor
Seoul National University Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.Stage II-IVB Operable HNSCC Oral CavityHypopharynxOropharynxLarynxNCT03737968Yonsei University48
进行中（未招募）
不适用
Window of Opportunity Trial of durvalumab (MEDI4736) or durvalumab/tremelimumab as neoadjuvant chemotherapy to identify immune dynamics in surgically resectable head and neck cancer patients.KCT0003333Yonsei University Health System, Severance Hospital48
撤回
2 期
Chemo-free BRCA-targeted Neoadjuvant StrategyTNBC - Triple-Negative Breast CancerBRCA1 MutationBRCA2 MutationNCT05209529European Organisation for Research and Treatment of Cancer - EORTC
尚未招募
不适用
Window of opportunity trial of durvalumab (MEDI4736) to identify immune dynamics in operable non-small cell lung cancer (NSCLC) (MIRACLE)KCT0006973Yonsei University Health System, Severance Hospital25
招募中
1 期
Olaparib and durvalumab before surgery as treatment for patients with a BRCA-associated triple negative subtype of breast cancer (NOBLE)Triple negative breast cancerMedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-003594-33-ITEORTC AISBL/IVZW152